
Paradigm BioDevices marked the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System. QuickDraw is a percutaneous or MIS bone grafting system developed to address risk factors associated with iliac crest bone grafting.
QuickDraw employs a tiny MIS or percutaneous incision to excise precise quantities of morselized autograft bone. Numerous independent and Level 1 metadata studies have confirmed that MIS autograft can be taken both safely and effectively with fewer patient complications and superior fusion rates than bone substitutes.
“We are grateful for the continued confidence and support we’ve received from our valued customers and distributors,” says Founder & President Mike O’Neill. “In an era when industry competitors are spending tens of millions marketing bone graft substitutes attacking the efficacy of autograft, we are thrilled to see the unwavering appreciation for, and continuous acceptance of, our MIS autografting products.”
Source: Paradigm Biosciences
Paradigm BioDevices marked the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System. QuickDraw is a percutaneous or MIS bone grafting system developed to address risk factors associated with iliac crest bone grafting.
QuickDraw employs a tiny MIS or percutaneous incision to excise precise quantities of morselized...
Paradigm BioDevices marked the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System. QuickDraw is a percutaneous or MIS bone grafting system developed to address risk factors associated with iliac crest bone grafting.
QuickDraw employs a tiny MIS or percutaneous incision to excise precise quantities of morselized autograft bone. Numerous independent and Level 1 metadata studies have confirmed that MIS autograft can be taken both safely and effectively with fewer patient complications and superior fusion rates than bone substitutes.
“We are grateful for the continued confidence and support we’ve received from our valued customers and distributors,” says Founder & President Mike O’Neill. “In an era when industry competitors are spending tens of millions marketing bone graft substitutes attacking the efficacy of autograft, we are thrilled to see the unwavering appreciation for, and continuous acceptance of, our MIS autografting products.”
Source: Paradigm Biosciences
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.